体内分布
生物利用度
药理学
药物输送
脂质体
肺
医学
吸入
药品
靶向给药
微泡
毒品携带者
信使核糖核酸
分布(数学)
化学
生物化学
体外
内科学
麻醉
数学分析
小RNA
数学
有机化学
基因
作者
Kristen D. Popowski,Blanca López de Juan Abad,Arianna George,Dylan Silkstone,Elizabeth Belcher,Jae-Wook Chung,Asma Ghodsi,Halle Lutz,Jada Davenport,Mallory Flanagan,Jorge A. Piedrahita,Phuong‐Uyen Dinh,Ke Cheng
出处
期刊:Extracellular vesicle
日期:2022-12-01
卷期号:1: 100002-100002
被引量:61
标识
DOI:10.1016/j.vesic.2022.100002
摘要
Respiratory diseases are among the leading causes of morbidity and mortality worldwide, coupled with the ongoing coronavirus disease 2019 (COVID-19) pandemic. mRNA lipid nanoparticle (LNP) vaccines have been developed, but their intramuscular delivery limits pulmonary bioavailability. Inhalation of nanoparticle therapeutics offers localized drug delivery that minimizes off targeted adverse effects and has greater patient compliance. However, LNP platforms require extensive reformulation for inhaled delivery. Lung-derived extracellular vesicles (Lung-Exo) offer a biological nanoparticle alternative that is naturally optimized for mRNA translation and delivery to pulmonary cells. We compared the biodistribution of Lung-Exo against commercially standard biological extracellular vesicles (HEK-Exo) and LNPs (Lipo), where Lung-Exo exhibited superior mRNA and protein cargo distribution to and retention in the bronchioles and parenchyma following nebulization administration. This suggests that inhaled Lung-Exo can deliver mRNA and protein drugs with enhanced pulmonary bioavailability and therapeutic efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI